alexa Treatment Of BCC: The Future Of Non-invasive Treatments
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Clinical & Experimental Dermatology
April 14-16, 2014 Hilton San Antonio Airport, TX, USA

Klara Mosterd
ScientificTracks Abstracts: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554.C1.013
Abstract
Although surgical excision is still the gold standard treatment for BCC, the high incidence of BCC necessitates the use and further development of non-invasive therapies. Individual treatment may be offered based on guidelines and randomized trials, such as the trial we recently published in the Lancet Oncology comparing 3 topical treatments for superficial BCC. The choice for a treatment is not only based on response rates, but also involves practical aspects, cosmetic result and costs. Development of topical and systemic targeted therapy, such as SMO inhibition has opened new perspectives. However the cure rate of none of those treatments equals that of surgical excision. Probably, because more pathways are involved in the development of BCC. We performed mutation analysis in tissue secondary resistant to systemic SMO inhibition. The found information may offer insight in how we can improve targeted treatments. Although second-generation SMO-antagonists have already been developed, a different option is to combine different treatments, which is common in other oncological treatments. Targeting GLI may be an option and also Itraconazole has been found to inhibit the Hh pathway. We recently performed a phase 3 trial to investigate the effects of topical application of diclofenac 3% and/or calcitriol 3ug/g on BCC. We found a good clinical response of the diclofenac cream to superficial BCC�s. Results of this trial will be presented. The future of BCC treatment is non-invasive treatment. Combination of different agents may have the advantage of additive inhibitory effects and possibly minimizing the development of tumor resistance to a drug.
Biography

Klara Mosterd has completed her Ph.D. at the Maastricht University Medical Centre at the age of 30, one year after becoming a dermatologist. She is part of the Head and Neck team and next to her clinical work as a dermatologist specialized in oncology has conducted large phase 3 trials that have been published in reputed journals such as the Lancet Oncology. She is now focusing on translational research for BCC treatments.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

p[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords